Specific randomized clinical trials, or real-life trials were performed and published, with the aim of assessing the effect of omalizumab (anti-IgE), benralizumab (anti IL-5 receptor), mepolizumab (anti circulating IL-5), reslizumab (anti circulating IL-5), tezepelumab (anti thymic stromal lymphopoietin (TSLP), and dupilumab (anti IL-4 receptor α) in CRSwNP, with promising results. The gene discussed is IGHE; the disease is chronic rhinosinusitis with nasal polyps.